# Pathway Genomics Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pathway-genomics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.omecare.com
- Total disclosed funding: $40M
- Latest round: Series E (Jan 5, 2016)
- Investors on record: 4

## About

Pathway Genomics Corporation is a biotechnology firm that provides innovative genetic testing solutions aimed at enhancing health and wellness through personalized medicine.Pathway Genomics Corporation was founded in 2008 and is headquartered in San Diego, US. The company specializes in genetic testing and has undergone strategic pivots in its operations. In January 2016, the company raised USD 40 mn in Series E funding led by Watson Group Investments, marking a significant milestone in its funding history. The total amount raised by Pathway Genomics to date is USD 40 mn across five deals.Pathway Genomics Corporation specializes in a diverse range of genetic testing products and services that cater to the healthcare sector. Their core offerings include advanced genetic tests that help inform health decisions and enable personalized treatment options. The company serves a broad audience, including healthcare providers and individual consumers, to enhance health management strategies through genetic insights. These services are available in North America and select European markets, contributing to their operational footprint in the personalized medicine industry.Pathway Genomics Corporation's revenue model is built on direct sales of genetic testing services to healthcare providers and consumers. They emphasize building long-term relationships through subscription services related to genetic testing and personalized health insights. These structured transactions are primarily B2B, allowing clients to order genetic tests in bulk, benefiting from competitive pricing for essential health evaluations.Pathway Genomics Corporation plans to leverage its recent USD 40 mn Series E funding to introduce new genetic testing products aimed at enhancing personalized medicine by the end of 2016. The company also intends to expand its market reach into additional European regions, targeting growth in both the UK and Germany by 2018. This strategy aims to enhance their product offerings and geographic presence, aligning with the increasing demand for personalized health solutions.

## Funding rounds

- Series E, Jan 5, 2016, $40M — Watson Group Investments
- Series A, Jul 14, 2009 — Edelson Technology Partners, Western Technology Investment, Founders Fund

## Investors

- Edelson Technology Partners (https://capitalatlas.ai/funds/edelson-technology-partners) — Series A
- Western Technology Investment (https://capitalatlas.ai/funds/western-technology-investment) — Series A
- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Series A
- Watson Group Investments (https://capitalatlas.ai/funds/watson-group-investments) — Series E